Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M. Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol. 1999 Apr;45(4):537-41. PubMed.
AlzBiomarker Database
Meta-Analysis
- AD vs CTRL : Aβ40 (Plasma and Serum)
- CTRL vs AD : Aβ40 (Plasma and Serum)
- AD vs CTRL : Aβ42 (Plasma and Serum)
- CTRL vs AD : Aβ42 (Plasma and Serum)
Curated Study Data
| Biomarker (Source) |
Cohort (N) |
Measurement Mean ± SD |
Method; Assay Name; Manufacturer |
Diagnostic Criteria |
|---|---|---|---|---|
| Aβ40 (Plasma) |
AD (36) |
94.5 ± 31.2 fmol/mL |
ELISA; Other/Not Specified; In-house |
McKhann et al., 1984 |
| Aβ40 (Plasma) |
CTRL (26) |
99.6 ± 39.1 fmol/mL |
ELISA; Other/Not Specified; In-house |
|
| Aβ42 (Plasma) |
AD (36) |
30.6 ± 10.9 fmol/mL |
ELISA; Other/Not Specified; In-house |
McKhann et al., 1984 |
| Aβ42 (Plasma) |
CTRL (26) |
21.1 ± 11.2 fmol/mL |
ELISA; Other/Not Specified; In-house |
Recommends
Please login to recommend the paper.
Comments
Osaka City University Medical School
The paper presents a new methodological view to measure Abeta, too.
Make a Comment
To make a comment you must login or register.